Profile data is unavailable for this security.
About the company
GRAIL, Inc., formerly GRAIL, LLC, is a healthcare company, which is engaged in saving lives and shifting the paradigm in early cancer detection. It is focused on alleviating the global burden of cancer by using next-generation sequencing, population-scale clinical studies, and machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. Its targeted methylation-based platform can support the continuum of care for screening and precision oncology, including multi-cancer early detection in symptomatic patients, risk stratification, minimal residual disease detection, biomarker subtyping, treatment and recurrence monitoring. Its products include Galleri and Beyond. The Galleri test is a commercially available screening test for early detection of multiple types of cancer, which is termed multi-cancer early detection (MCED). Galleri screening test results can help guide next steps for a diagnosis of cancer by healthcare providers.
- Revenue in USD (TTM)100.18m
- Net income in USD-1.49bn
- Incorporated2020
- Employees1.36k
- LocationGrail Inc1525 O'brien DriveMENLO PARK 94025United StatesUSA
- Phone+1 (650) 771-9796
- Fax+1 (302) 655-5049
- Websitehttps://www.galleri.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Altimmune Inc | 410.00k | -92.77m | 451.65m | 59.00 | -- | 2.61 | -- | 1,101.58 | -1.59 | -1.59 | 0.007 | 2.44 | 0.0022 | -- | 1.47 | 6,949.15 | -49.42 | -39.62 | -53.14 | -42.58 | -- | -- | -22,626.10 | -1,811.89 | -- | -- | 0.00 | -- | 726.47 | -47.15 | -4.41 | -- | -45.92 | -- |
| Aura Biosciences Inc | 0.00 | -78.65m | 453.32m | 88.00 | -- | 2.17 | -- | -- | -1.86 | -1.86 | 0.00 | 4.22 | 0.00 | -- | -- | 0.00 | -35.66 | -- | -37.16 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -30.03 | -- | -- | -- |
| Nkarta Inc | 0.00 | -116.20m | 455.93m | 150.00 | -- | 0.9624 | -- | -- | -2.35 | -2.35 | 0.00 | 6.72 | 0.00 | -- | -- | 0.00 | -22.45 | -32.39 | -23.55 | -34.05 | -- | -- | -- | -372,519.20 | -- | -- | 0.00 | -- | -- | -- | -3.22 | -- | 106.05 | -- |
| Absci Corp | 5.35m | -109.19m | 463.64m | 155.00 | -- | 1.93 | -- | 86.71 | -1.17 | -1.17 | 0.0569 | 2.12 | 0.0187 | -- | 7.82 | 34,496.77 | -38.26 | -- | -42.14 | -- | -- | -- | -2,042.01 | -- | -- | -107.74 | 0.0298 | -- | -0.5046 | -- | -5.40 | -- | -- | -- |
| Northwest Biotherapeutics Inc | 1.34m | -72.21m | 465.10m | 25.00 | -- | -- | -- | 348.13 | -0.0629 | -0.0629 | 0.0012 | -0.0447 | 0.0435 | -- | -- | 53,440.00 | -228.72 | -381.58 | -- | -- | -- | -- | -5,258.91 | -6,479.25 | -- | -10.49 | -- | -- | 14.80 | 36.21 | 38.71 | -- | 77.88 | -- |
| Voyager Therapeutics Inc | 119.04m | -3.04m | 477.03m | 162.00 | -- | 1.40 | 314.25 | 4.01 | -0.1812 | -0.1812 | 2.44 | 6.28 | 0.2954 | -- | 8.27 | 734,839.50 | -0.7554 | 0.6378 | -0.8534 | 0.8203 | -- | -- | -2.56 | 1.30 | -- | -- | 0.00 | 0.00 | 511.16 | 101.01 | 385.14 | -- | -5.43 | -- |
| Heron Therapeutics Inc | 132.10m | -80.95m | 482.09m | 126.00 | -- | -- | -- | 3.65 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
| Third Harmonic Bio Inc | 0.00 | -29.60m | 495.49m | 31.00 | -- | 1.85 | -- | -- | -0.7475 | -0.7475 | 0.00 | 6.55 | 0.00 | -- | -- | 0.00 | -10.53 | -- | -10.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 12.32 | -- | -- | -- |
| Anavex Life Sciences Corp | 0.00 | -40.59m | 500.23m | 40.00 | -- | 3.66 | -- | -- | -0.4962 | -0.4962 | 0.00 | 1.61 | 0.00 | -- | -- | 0.00 | -26.73 | -40.04 | -28.98 | -43.97 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 0.9857 | -- | -- | -- |
| Grail Inc | 100.18m | -1.49bn | 500.82m | 1.36k | -- | 0.1145 | -- | 5.00 | -56.16 | -56.16 | 3.77 | 140.84 | -- | -- | -- | 74,763.43 | -- | -47.45 | -- | -48.55 | 41.91 | -- | -1,488.21 | -5,118.86 | -- | -- | 0.00 | -- | 67.61 | -- | 72.85 | -- | -4.22 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -129.44m | 508.07m | 186.00 | -- | 1.96 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
| Fate Therapeutics Inc | 6.48m | -190.05m | 519.07m | 181.00 | -- | 1.22 | -- | 80.13 | -1.92 | -1.92 | 0.0653 | 3.74 | 0.0108 | -- | 0.9024 | 35,790.05 | -31.67 | -31.82 | -34.36 | -36.05 | -- | -- | -2,933.79 | -359.33 | -- | -- | 0.00 | -- | -34.03 | 68.05 | 42.88 | -- | 21.72 | -- |
| Y-mAbs Therapeutics Inc | 84.50m | -21.67m | 533.61m | 100.00 | -- | 5.38 | -- | 6.32 | -0.496 | -0.496 | 1.93 | 2.26 | 0.6481 | 1.31 | 4.30 | 844,990.00 | -16.62 | -44.23 | -19.95 | -50.45 | 86.53 | -- | -25.64 | -181.13 | 5.67 | -- | 0.00 | -- | 29.96 | -- | 77.58 | -- | -- | -- |
| Fulcrum Therapeutics Inc | 2.51m | -99.43m | 534.52m | 76.00 | -- | 2.50 | -- | 212.96 | -1.61 | -1.61 | 0.0406 | 3.44 | 0.0091 | -- | 2.14 | 33,026.32 | -35.91 | -50.55 | -37.62 | -55.91 | -- | -- | -3,961.20 | -1,189.10 | -- | -- | 0.00 | -- | -55.77 | -- | 11.41 | -- | -43.70 | -- |
Data as of Jul 23 2024. Currency figures normalised to Grail Inc's reporting currency: US Dollar USD
2.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| CaaS Capital Management LPas of 30 Jun 2024 | 249.39k | 0.80% |
| Swedbank Robur Fonder ABas of 30 Jun 2024 | 92.78k | 0.30% |
| PGGM Vermogensbeheer BVas of 30 Jun 2024 | 68.56k | 0.22% |
| Nikko Asset Management Co., Ltd.as of 30 Jun 2024 | 63.26k | 0.20% |
| Raymond James & Associates, Inc. (Invt Mgmt)as of 30 Jun 2024 | 47.00k | 0.15% |
| Douglas Lane & Associates LLCas of 30 Jun 2024 | 41.29k | 0.13% |
| TCW Asset Management Co. LLCas of 30 Jun 2024 | 40.00k | 0.13% |
| SG Americas Securities LLCas of 30 Jun 2024 | 39.83k | 0.13% |
| KBC Asset Management NVas of 30 Jun 2024 | 23.86k | 0.08% |
| A. D. Beadell Investment Counsel, Inc.as of 30 Jun 2024 | 23.59k | 0.08% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
